Literature DB >> 30349082

Cytotoxic anti-circumsporozoite antibodies target malaria sporozoites in the host skin.

Eduardo Aliprandini1, Joana Tavares2,3, Raquel Hoffmann Panatieri1,4, Sabine Thiberge1,5, Marcio Massao Yamamoto4, Olivier Silvie6, Tomoko Ishino7, Masao Yuda8, Sylvie Dartevelle9, François Traincard9, Silvia Beatriz Boscardin10, Rogerio Amino11.   

Abstract

The circumsporozoite protein (CSP) is the major surface protein of malaria sporozoites (SPZs), the motile and invasive parasite stage inoculated in the host skin by infected mosquitoes. Antibodies against the central CSP repeats of different plasmodial species are known to block SPZ infectivity1-5, but the precise mechanism by which these effectors operate is not completely understood. Here, using a rodent Plasmodium yoelii malaria model, we show that sterile protection mediated by anti-P. yoelii CSP humoral immunity depends on the parasite inoculation into the host skin, where antibodies inhibit motility and kill P. yoelii SPZs via a characteristic 'dotty death' phenotype. Passive transfer of an anti-repeat monoclonal antibody (mAb) recapitulates the skin inoculation-dependent protection, in a complement- and Fc receptor γ-independent manner. This purified mAb also decreases motility and, notably, induces the dotty death of P. yoelii SPZs in vitro. Cytotoxicity is species-transcendent since cognate anti-CSP repeat mAbs also kill Plasmodium berghei and Plasmodium falciparum SPZs. mAb cytotoxicity requires the actomyosin motor-dependent translocation and stripping of the protective CSP surface coat, rendering the parasite membrane susceptible to the SPZ pore-forming-like protein secreted to wound and traverse the host cell membrane6. The loss of SPZ fitness caused by anti-P. yoelii CSP repeat antibodies is thus a dynamic process initiated in the host skin where SPZs either stop moving7, or migrate and traverse cells to progress through the host tissues7-9 at the eventual expense of their own life.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30349082     DOI: 10.1038/s41564-018-0254-z

Source DB:  PubMed          Journal:  Nat Microbiol        ISSN: 2058-5276            Impact factor:   17.745


  24 in total

1.  A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver.

Authors:  Lawrence T Wang; Lais S Pereira; Yevel Flores-Garcia; James O'Connor; Barbara J Flynn; Arne Schön; Nicholas K Hurlburt; Marlon Dillon; Annie S P Yang; Amanda Fabra-García; Azza H Idris; Bryan T Mayer; Monica W Gerber; Raphael Gottardo; Rosemarie D Mason; Nicole Cavett; Reid B Ballard; Neville K Kisalu; Alvaro Molina-Cruz; Jorgen Nelson; Rachel Vistein; Carolina Barillas-Mury; Rogerio Amino; David Baker; Neil P King; Robert W Sauerwein; Marie Pancera; Ian A Cockburn; Fidel Zavala; Joseph R Francica; Robert A Seder
Journal:  Immunity       Date:  2020-09-17       Impact factor: 31.745

2.  The light chain of the L9 antibody is critical for binding circumsporozoite protein minor repeats and preventing malaria.

Authors:  Lawrence T Wang; Nicholas K Hurlburt; Arne Schön; Barbara J Flynn; Yevel Flores-Garcia; Lais S Pereira; Patience K Kiyuka; Marlon Dillon; Brian Bonilla; Fidel Zavala; Azza H Idris; Joseph R Francica; Marie Pancera; Robert A Seder
Journal:  Cell Rep       Date:  2022-02-15       Impact factor: 9.423

3.  Germinal center activity and B cell maturation are associated with protective antibody responses against Plasmodium pre-erythrocytic infection.

Authors:  Ganesh Ram R Visweswaran; Kamalakannan Vijayan; Ramyavardhanee Chandrasekaran; Olesya Trakhimets; Samantha L Brown; Vladimir Vigdorovich; Ashton Yang; Andrew Raappana; Alex Watson; William Selman; Meghan Zuck; Nicholas Dambrauskas; Alexis Kaushansky; D Noah Sather
Journal:  PLoS Pathog       Date:  2022-07-06       Impact factor: 7.464

Review 4.  Antibodies against Plasmodium falciparum malaria at the molecular level.

Authors:  Jean-Philippe Julien; Hedda Wardemann
Journal:  Nat Rev Immunol       Date:  2019-08-28       Impact factor: 53.106

5.  Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein.

Authors:  Rodolfo F Marques; Alba Marina Gimenez; Eduardo Aliprandini; Janaina T Novais; Diego P Cury; Ii-Sei Watanabe; Mariana R Dominguez; Eduardo L V Silveira; Rogerio Amino; Irene S Soares
Journal:  Vaccines (Basel)       Date:  2020-04-19

Review 6.  Intravital imaging of host-parasite interactions in skin and adipose tissues.

Authors:  Mariana De Niz; Gavin R Meehan; Nicolas M B Brancucci; Matthias Marti; Brice Rotureau; Luisa M Figueiredo; Friedrich Frischknecht
Journal:  Cell Microbiol       Date:  2019-04-03       Impact factor: 3.715

7.  A tracer-based method enables tracking of Plasmodium falciparum malaria parasites during human skin infection.

Authors:  Béatrice M F Winkel; Clarize M de Korne; Matthias N van Oosterom; Diego Staphorst; Anton Bunschoten; Marijke C C Langenberg; Séverine C Chevalley-Maurel; Chris J Janse; Blandine Franke-Fayard; Fijs W B van Leeuwen; Meta Roestenberg
Journal:  Theranostics       Date:  2019-04-13       Impact factor: 11.556

Review 8.  Vaccination With Sporozoites: Models and Correlates of Protection.

Authors:  Yun Shan Goh; Daniel McGuire; Laurent Rénia
Journal:  Front Immunol       Date:  2019-06-05       Impact factor: 7.561

Review 9.  Complement in malaria immunity and vaccines.

Authors:  Liriye Kurtovic; Michelle J Boyle; D Herbert Opi; Alexander T Kennedy; Wai-Hong Tham; Linda Reiling; Jo-Anne Chan; James G Beeson
Journal:  Immunol Rev       Date:  2019-09-26       Impact factor: 12.988

Review 10.  Immune responses to malaria pre-erythrocytic stages: Implications for vaccine development.

Authors:  Kelvin Mokaya Abuga; William Jones-Warner; Julius Clemence R Hafalla
Journal:  Parasite Immunol       Date:  2020-10-09       Impact factor: 2.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.